Cancer endocrinology: noticeable developments in the last decade

[...]the author could not mention all researchers and subjects worth mentioning, as the references list length is finite. [...]we ask readers to be excused in case some important article is omitted and certain topics are not covered. Another innovation is the use of the combination of conjugated estrogens and bazedoxifene (antiestrogen), which in theory should not increase BC or EC risk, while offering all the benefits of postmenopausal estrogen therapy (e.g.,vasomotor symptoms attenuation and lipidemia control)(10). [...]while diabetes mellitus Type 2 is an important risk factor for some tumors (cancer of liver, pancreas andendometrium, among others), it has no influence on BC incidence in premenopausal females and even has a negative correlation to prostate cancer risk, which is probably due to lower androgens andIGFBP-3 levels in circulation(18).No doubt, the last decade has seen increased interest in prostate cancer including issues such as the role of estrogens, the importance of cancer-repopulating and castrate-resistant cells, hormone-metabolic consequences of complete androgenic blockade and the discovery of the new antiandrogens, among others(19 ,20). Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials.